TDs call on HSE Drugs Group to reveal why they decided not to fund Skyclarys

It follows the story of the Coady family in Cork who lost their son Rory, 13, to Friedrich’s ataxia in September. Their 16-year-old son, Paudie, also has the condition
Craig Coady: 'I was actually gobsmacked; they basically said it wasn’t worth it — poor value for money — we’re talking about my child’s life, and I’ve already lost a child.' Picture: Chani Anderson

Craig Coady: 'I was actually gobsmacked; they basically said it wasn’t worth it — poor value for money — we’re talking about my child’s life, and I’ve already lost a child.' Picture: Chani Anderson

Politicians have called for “transparency” around the HSE Drugs Group decision not to recommend the drug Skyclarys, amid calls for the Oireachtas Health Committee to be recalled from its summer break.

Skyclarys is used to treat Friedreich’s ataxia, a rare genetic disorder that causes progressive damage to the nervous system and can lead to heart complications.

You have reached your article limit. Already a subscriber? Sign in

Save €40 on an Annual Subscription.​

Continue reading within unlimited digital access and exclusive subscriber benefits.

Cancel anytime

More in this section

Politics

Newsletter

From the corridors of power to your inbox ... sign up for your essential weekly political briefing.

Cookie Policy Privacy Policy Brand Safety FAQ Help Contact Us Terms and Conditions

© Examiner Echo Group Limited